Research programme: antibody-drug conjugates - Mersana Therapeutics/Millennium

Drug Profile

Research programme: antibody-drug conjugates - Mersana Therapeutics/Millennium

Alternative Names: Fleximer® antibody-drug conjugate - Mersana Therapeutics/Millennium

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Mersana Therapeutics; Millennium
  • Developer Mersana Therapeutics; Takeda Oncology
  • Class Antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Mar 2017 Mersana Therapeutics has patent protection for Fleximer-ADC platform technology in the European Union
  • 12 Jan 2015 Mersana Therapeutics and Takeda expand their ongoing collaboration to create Fleximer® antibody-drug conjugate drug candidates
  • 12 Jan 2015 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top